Chemistry and biology of some low molecular weight boron compounds for Boron Neutron Capture Therapy

Journal of Neuro-Oncology

Volumn 33, Issue 1-2, 1997, Pages 41-52

  Sjöberg, Stefan ^a   Carlsson, Jörgen ^a   Ghaneolhosseini, Hadi ^a   Gedda, Lars ^a   Hartman, Torbjörn ^a   Malmquist, Jonas ^a   Naeslund, Charlotta ^a   Olsson, Pär ^a   Tjarks, Werner ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Boron neutron capture therapy (BNCT); Boronated amino acids; Boronated DNA intercalators; Boronated DNA targeting compounds; Boronated DNA alkylators; Carboranylamines; o Carboranyl amino acids; p Carboranylalanine

Indexed keywords

BORON DERIVATIVE; BORONOAMINO ACID; INTERCALATING AGENT;

ARTICLE; CELL NUCLEUS; DNA DRUG COMPLEX; DRUG SYNTHESIS; DRUG TARGETING; GENE TARGETING; HUMAN; LIPOPHILICITY; NEUTRON CAPTURE THERAPY;

EID: 0030896009     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1005756929011     Document Type: Article

References (75)

1. Barth RF, Soloway AH, Fairchild RB: Boron neutron capture therapy for cancer. Cancer Res 50: 1061-1070, 1990 (Review)
2. Barth RF, Soloway AH, Fairchild RG, Brugger RM: Boron neutron capture therapy for cancer. Realities and prospects. Cancer 70: 2995-3007, 1992 (Review)
3. Carlsson J, Sjöberg S, Larsson B: Present status of boron neutron capture therapy. Acta Oncol 31: 803-814, 1992 (Review)
4. Hawthorne MF: The role of chemistry in the development of boron neutron capture therapy of cancer. Angew Chem Int Ed Engl 32: 950-984, 1993 (Review)
5. Kobayashi T, Kanda K: Analytical calculation of boron-10 dosage in cell nucleus for neutron capture therapy. Radiat Res 91: 77-94, 1982
6. 7Li reaction in cells and tissues and its implication for boron neutron capture therapy. Radiat Res 111: 14-25, 1987
7. Hartman T, Carlsson J: Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy. Radiother Oncol 31: 61-75, 1994
8. Morin C: The chemistry of boron analogues of biomolecules. Tetrahedron 50: 12521-12569, 1994 (Review)
9. Goudgaon NM, Fulcrand El-Kattan G, Schinazi RF: Boron containing pyrimidines, nucleosides, and oligonucleotides for neutron capture therapy. Nucleosides Nucleotides 13: 849-880, 1994 (Review)
10. Wyzlic IM, Tjarks W, Soloway AH, Anisuzzaman AKM, Rong F-G, Barth RF: Strategies for the design and synthesis of boronated nucleic acid and protein components as potential delivery agents for neutron capture therapy. Int J Radiat Oncol Biol Phys 28: 1203-1213, 1994 (Review)
11. Lesnikowski ZJ, Schinazi RF: Boron neutron capture therapy of cancer: Nucleic bases, nucleosides, and oligonucleotides as boron carriers. Polish J Chem 69: 827-840, 1995 (Review)
12. Sood A, Spielvogel BF, Powell WJ, Bastow KF, Miller MC, Hall IH: Cytotoxicity of ribo- and arabinoside boron nucleosides in tissue culture cells. Anticancer Res 14: 1483-1488, 1994
13. Burnham BS, Chen SY, Rajendran KG, Sood A, Spielvogel BF, Shaw BR, Hall IH: The synthesis of amine-borane adducts of cyclohexylamine, toluidine, and 3′-aminodideoxynucleosides and evaluation of their pharmacological activity. In: Kabalka GW (ed) Current Topics in the Chemistry of Boron. The Royal Society of Chemistry, Cambridge, UK 189-192, 1994
14. 10B carriers and their selective uptake by cancer cells. In: Kabalka GW (ed) Current Topics in the Chemistry of Boron. The Royal Society of Chemistry, Cambridge, UK 1149-1154, 1994
15. Yamamoto Y, Seko T, Nakamura H, Nemoto H, Hojo H, Mukai N, Hashimoto Y: Synthesis of carboranes containing nucleoside bases. Unexpectedly high cytostatic and cytocidal toxicity towards cancer cells. J Chem Soc, Chem Commun 157-158, 1992
16. Schinazi RF, Goudgaon NM, Fulcrand G, El Kattan Y, Lesnikowski Z, Ullas G, Moravek J, Liotta DC: Cellular pharmacology and biological activity of 5-carboranyl-2′-deoxyuridine. Int J Radiat Oncol Biol Phys 28: 1113-1120, 1994
17. Rong F-G, Solowy AH, Ikeda S, Ives DH: Synthesis of 5-tethered boron-containing pyrimidine nucleosides for BNCT. In: Mishima Y (ed) Neutron Capture Therapy for Human Cancer. Plenum Press, New York, London, 1996, in press
18. Haslinger F, Soloway AH: Carboranes. II. An analog of 1,4-(dimethanesulfoxy)butane. J Med Chem 9: 792, 1966
19. Soloway AH, Butler DN: Carboranes. I. Nitrogen mustards. J Med Chem 9: 411-412, 1966
20. Soloway AH: Boron compounds in cancer therapy. In: McCloskey AL, Steinberg H (eds) Progress in Boron Chemistry, Vol. I. Pergamon Press Inc., New York, NY 203-234, 1964
21. Davis MA, Soloway AH: Carboranes. III. Boron-containing acridines. J Med Chem 10: 730-732, 1967
22. Roscoe CW, Phillips JW, Gillchriest WC: New compounds: Organoboron derivatives of tetracyclines. I. Synthesis of carboxamido derivatives of tetracycline with perhydro-2-phenyl-1,3,6,2-dioazaborocine. J Pharm Sci 66: 1505-1507, 1977
23. 2) as the boron-10 carrier in neutron capture therapy. Oncology 27: 97-104, 1973
24. LeGuerrier JM, Ayre JE, Gillchriest WC: Studies on the intracellular distribution of boron modified tetracycline analogs in tumor cells. A preliminary report. Oncology 25: 97-103, 1971
25. Kelly DP, Bateman SA, Martin RF, Reum ME, Rose M, Whittacker ARD: DNA binding compounds. V. Synthesis and characterization of boron-containing bibenzimidazoles related to the DNA minor groove binder, Hoechst 33258. Aust J Chem 47: 247-262, 1994
26. 157Gd-labelled ligands for neutron capture therapy. In: Allen BJ, Moore DE, Harrington BV (eds) Progress in Neutron Capture Therapy for Cancer. Plenum Press, New York, London 231-233, 1992
27. 157Gd-labelled DNA ligands for neutron capture therapy. In: Allen BJ, Moore DE, Harrington BV (eds) Progress in Neutron Capture Therapy for Cancer. Plenum Press, New York, London 357-361, 1992
28. 10B-labelled DNA ligand. In: Soloway AH, Barth RF, Carpenter DE (eds) Advances in Neutron Capture Therapy. Plenum Press, New York, London 377-381, 1993
29. Argentini M, dos Santos DF, Weinreich R, Hansen HJ: Chemical synthesis of a dodecaborane derivative of Hoechst 33258 for BNCT. In: Amaldi U, Larsson B (eds) Hardrontherapy in Oncology. Elsevier Science B.V., Amsterdam 555-559, 1994
30. 157Gd-labelled DNA ligands. In: Soloway AH, Barth RF, Carpenter DE (eds) Advances in Neutron Capture Therapy. Plenum Press, New York, London 383-387, 1993
31. Yamamoto Y, Cai J, Nakamura H, Sadayori N, Asao N, Nemoto H: Synthesis of netropsin and distamycin analogues bearing o-carborane and their DNA recognition. J Org Chem 60: 3352-3357, 1995
32. Tjarks W, Malmquist J, Gedda L, Sjöberg S, Carlsson J: Synthesis and initial biological evaluation of carborane-containing phenanthridinium derivatives. In: Mishima Y (ed) Neutron Capture Therapy for Human Cancer. Plenum Press, New York, London, 1996, in press
33. Cohen GM, Cullis PM, Hartley JA, Mather A, Symons MCR, Wheelhouse RT: Targeting of cytotoxic agents by polyamines: Synthesis of a chlorambucil-spermidine conjugate. J Chem Soc, Chem Commun 298-300, 1992
34. Hariharan JR, Wyzlic IM, Soloway AH: Synthesis of novel boron-containing polyamines - agents for DNA targeting in neutron capture therapy. Polyhedron 14: 823-825, 1995
35. Soloway AH, Wyzlic IM, Tjarks W, Hariharan JR, Burgos-Foster M, Barth RF: New small molecular weight agents for boron neutron capture therapy. In: Mishima Y (ed) Neutron Capture Therapy for Human Cancer. Plenum Press, New York, London, 1996, in press
36. Coderre JA, Glass JD, Fairchild RG, Roy U, Fand I: Selective targeting of boronophenylalanine to melanoma in BALB/c mice for neutron capture therapy. Cancer Res 47: 6377-6383, 1987
37. Papaspyrou M, Feinendegen LE, Müller-Gärtner H-W: Preloading with L-tyrosine increases the uptake of boronophenylalanine in mouse melanoma cells. Cancer Res 54: 6311-6314, 1994
38. Malan C, Morin C: Synthesis of 4-borono-L-phenylalanine. Synlett 167-168, 1996
39. Yoshino K, Maruyama T, Takahashi H, Mori Y, Kakihana H, Mishima Y, Ichihashi M, Honda C, Shiono H: Synthesis of o-and m-boronophenylalanine. In: Soloway AH, Barth RF, Carpenter DE (eds) Advances in Neutron Capture Therapy. Plenum Press, New York, London 261-264, 1993
40. Yoshino K, Koike N, Kuroda Y, Mori Y: Examination of stability of p-, m-, o-boronophenylalanine in blood with high performance liquid chromatography. Abstr Sixth Int Symp Neutr Capt Ther Cancer p. 115, 1994
41. Yoshino K, Watanabe N, Takahashi H, Watanabe S, Mori Y: Chemical properties of p-, m-, o-boronophenylalanine. Abstr Sixth Int Symp Neutr Capt Ther Cancer p. 79, 1994
42. Kirihatha H, Morimoto T, Ichimoto I, Takagaki M: An efficient synthesis of p-boronophenylalanine and its homologues by reaction of ethyl isocyanoacetate with a p-formylbenzeneboronic acid derivative. Abstr Sixth Int Symp Neutr Capt Ther Cancer p. 79, 1994
43. Nemoto H, Cai J, Asao N, Iwamoto S, Yamamoto Y: Synthesis of biological properties of water-soluble p-boronophenylalanine derivatives. Relationship between water solubility, cytotoxicity, and cellular uptake. J Med Chem 38: 1673-1678, 1995
44. Zakharkin LI, Grebennikov AV, L'vov AI: Synthesis of some nitrogenous barene derivatives. Izv Akad Nauk SSSR Ser Khim 1: 106-112, 1970
45. Brattsev VA, Stanko VI: β-(o-Barenyl)alanine. Zh Obshch Khim 39: 1175-1176, 1969
46. Leukart O, Caviezel M, Eberle A, Escher E, Tun-Kyi A, Schwyzer R: L-o-Carboranylalanine, a boron analogue of phenylalanine. Helv Chim Acta 59: 2184-2187, 1976
47. Fauchère JL, Leukart O, Eberle A, Schwyzer R: The synthesis of [4-carboranylalanine, 5-leucin]-enkephalin. Helv Chim Acta 629: 1386-1395, 1979
48. We found that the enantiomeric purity was 97% [52] for L-Car prepared according to [47].
49. Andersson A, Andersson J, Burgman J-O, Capala J, Carlsson J, Condé H, Crawford J, Graffman S, Grusell E, Holmberg A, Johansson, Larsson BD, Larsson B, Liljefors T, Lindström P, Malmquist J, Pellettieri L, Pettersson O, Pontén J, Roberti A, Russel K, Reist H, Salford L, Sjöberg S, Stenerlöw B, Strömberg P, Westermark B: Programme for BNCT with accelerator-produced keV neutron and related chemical and biological studies. In: Allen BJ, Moore DE, Harrington BV (eds) Progress in Neutron Capture Therapy for Cancer. Plenum Press, New York 41-52, 1992
50. Sjöberg S, Hawthorne MF, Lindström P, Malmquist J, Carlsson J, Andersson A, Pettersson O: A symmetric synthesis of carboranyl amino acids with potential use in BNCT. In: Barth RF, Carpenter DE, Soloway AH (eds) Advances in Neutron Capture Therapy. Plenum Press, New York 269-273, 1993
51. Oppolzer W, Moretti R, Thomi S: A symmetric alkylations of a sultam-derived glycinate equivalent: practical preparation of enantiomerically pure α-amino acids. Tetrahedron Lett 30: 6009-6110, 1989
52. Lindström P: Boron neutron capture therapy. Synthesis of boron containing substances and tests of their cellular binding and toxicity. Acta Universitatis Uppsaliensis. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 32: 1994 (ISBN 91-554-3264-6)
53. Pettersson P, Malmquist J, Markides K, Sjöberg S: Determination of enantiomeric purity of (S)-carboranylalanine using open tubular column SFC. J Chromatogr 670: 239-242, 1994
54. Malmquist J: Boronated amines and amino acids for boron neutron capture therapy. Acta Universitatis Uppsaliensis. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 125, 1995 (ISBN 91-554-33531-9)
55. Radel PA, Kahl S: Enantioselective synthesis of an unnatural amino acid, L-carboranylalanine. In: Barth RF, Carpenter DE, Soloway AH (eds) Advances in Neutron Capture Therapy. Plenum Press, New York 277-280, 1993
56. Kahl S, Radel PA: Recent development in tumor-selective targeting of boron for neutron capture therapy: carboranylalanine. In: Kabalka GW (ed) Current Topic in the Chemistry of Boron. Royal Society of Chemistry, Cambridge 155-160, 1994
57. Karnbrock W, Musiol H-J, Moroder L: Enantioselective synthesis of S-o-carboranylalanine via methylated bislactim ethers of 2,5-diketopiperazines. Tetrahedron 51: 1187-1196, 1995
58. Wyzlic IM, Soloway AH: A general convenient way to carborane-containing amino acids for boron neutron capture therapy. Tetrahedron Lett 33: 7489-7490, 1992
59. Malmquist J, Carlsson J, Markides KE, Pettersson P, Olsson P, Sunnerheim-Sjöberg K, Sjöberg S: A symmetric synthesis of o- and p-carboranyl amino acids. In: Mishima Y (ed) Neutron Capture Therapy. Plenum Press, New York, 1996, in press
60. Sjöberg S, Carlsson J, Lindström P, Malmquist J: Carboranyl amino acids and amines with potential use in BNCT. In: Kabalka GW (eds) Current Topic in the Chemistry of Boron. Royal Society of Chemistry, Cambridge 173-176, 1994
61. Sjöberg S, Hawthorne MF, Wilmouth S, Lindström P: A symmetric synthesis of carboranyl amino acids with potential use in BNCT. Chem Eur J 1: 128-133, 1995
62. Prashar JK, Moore DE: Synthesis of carboanylphenylalanine for potential use in neutron capture therapy of melanoma. J Chem Soc Perkin Trans 1: 1051-1053, 1993
63. Prashar J, Lama D, Moore D: Synthesis of dihydroxycarboranyl phenylalanine for potential use in boron neutron capture therapy of melanoma. Tetrahedron Lett 34: 6779-6780, 1993
64. Kane R, Pak RH, Hawthorne MF: Solution-phase segment synthesis of boron-rich peptides. J Org Chem 58: 991-992, 1993
65. Varadarajan A, Hawthorne MF: Novel carboranyl acids and peptides: Reagents for antibody modification and subsequent neutron-capture studies. Bioconjugate Chem 2: 242-253, 1991
66. Paxton RJ, Beatty BG, Varadarajan A, Hawthorne MF: Carboranyl peptide-antibody conjugates for neutron capture therapy: Preparation, characterization, and in vivo evaluation. Bioconjugate Chem 3: 241-247, 1992
67. Leusch A, Jungblut L, Moroder L: Design and synthesis of carboranyl peptides as carriers of 1,2-Dicarbadodecaborane clusters. Synthesis 305-308, 1994
68. Wyzlic IM, Beeson J, Soloway AH: New unnatural boron-containing amino acids and peptides as potential delivery agents for neutron capture therapy. Abstr Sixt Int Symp Neutr Capt Ther Cancer p. 80, 1994
69. Pettersson O, Olsson P, Lindström P, Sjöberg S, Carlsson J: Penetration and binding of L- and D-carboranylalanine in human melanoma spheroids. Melanoma Res 3: 369-376, 1993
70. Pettersson O, Olsson P, Lindström P, Sjöberg S, Larsson BS, Carlsson J: Cellular binding of carboranylalanine and some effects of boron neutron capture: Analysis of cultured melanoma B16 cells. Acta Oncol 33: 658-691, 1994
71. Carlsson J, Gedda L, Grönvik C, Hartman T, Lindström A, Lindström P, Olsson P, Pontén J, Sjöberg S, Westermark B: Strategy for boron neutron capture therapy against tumor cells with over-expression of the epidermal growth factor-receptor. Int J Radiat Oncol Biol Phys 30: 105-115, 1993
72. Malmquist J, Sjöberg S: Synthesis of 2-[2-(3-aminopropyl)-1,2-dicarba-closo-dodecaborane(12)-1-ylmethoxy]-1,3- propanediol, a hydrophilically substituted aminoalkyl-o-carborane. Acta Chem Scand 48: 886-890, 1994
73. Lindström P, Olsson P, Malmqvist J, Pettersson J, Lemmen P, SjöbergS, Olin Å, Carlsson J: New carborane based compounds for boron neutron capture therapy. Binding and toxicity of ANC-1, DAC-1 and B-Et-11-OMe in cultured human glioma and mouse melanoma cells. Anti-Cancer Drugs 5: 43-52, 1994
74. Tilly N, Olsson P, Hartman T, Coderre J, Makar M, Malmquist J, Sjöberg S, Pettersson J, Carlsson J, Glimelius B: In vitro determination of toxicity, binding, retention, subcellular distribution and biological efficiency of the boron neutron capture reagent DAC-1. Radiotherapy and Oncology, 1996, in press
75. Olsson P, Lindström P, Tilly N, Black M, Malmquist J, Sjöberg S, Carlsson J: Uptake and biological effects of the carborane based boron compounds DAC-1 and DAAC-1. In: Mishima Y (ed) Neutron Capture Therapy. Plenum Press, New York, 1996, in press